Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Company Overview

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Key Stats

• Today's Range: C$12.97 to C$13.29
• 50-Day Range: C$11.00 to C$13.75
• 52-Week Range: C$5.65 to C$13.83
• Volume: 684 shs
• Average Volume: 1,012 shs
• Market Capitalization: C$369.89 million
• P/E Ratio: N/A
• Dividend Yield: 2.02%
• Price Target: N/A
• Consensus Rating: Strong Buy

FRX Stock Analysis - Frequently Asked Questions

How have FRX shares performed this year?

Fennec Pharmaceuticals' stock was trading at C$8.87 at the start of the year. Since then, FRX stock has increased by 49.8% and is now trading at C$13.29.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc. (TSE:FRX) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.10. Fennec Pharmaceuticals had a positive trailing twelve-month return on equity of 29.94% and a negative net margin of 2.30%.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 10/08/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:FRX
• CIK: N/A
• Web: fennecpharma.com
• Phone: +1-919-6364530
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 22.01
• P/E Growth: N/A
• Net Income: -C$800.44 thousand
• Net Margins: -2.30%
• Pretax Margin: N/A
• Return on Equity: 29.94%
• Return on Assets: 8.88%

Debt

• Debt-to-Equity Ratio: -620.83
• Current Ratio: 7.80
• Quick Ratio: 10.17

Sales & Book Value

• Annual Sales: C$33.30 million
• Price / Sales: 11.11
• Cash Flow: C$1.14 per share
• Price / Cash Flow: 11.66
• Book Value: C($0.19) per share
• Price / Book: -70.16

Miscellaneous

• Outstanding Shares: 27,832,000
• Free Float: N/A
• Market Cap: C$369.89 million
• Optionable: Not Optionable
• Beta: 2.48